The Research of Medical Science Review

Received: 17 December, 2024
Accepted: 17 January, 2025
Published: 27 January, 2025

ISSN: 3007-1208 | 3007-1216
Volume 3, Issue 1, 2025

IDENTIFICATION, EVALUATION, AND PREVENTION OF PREDOMINANT MICROORGANISMS CAUSING VENTILATOR-ASSOCIATED PNEUMONIA IN ICU PATIENTS

Mahnoor[*1], Dr. Adnan Hafeez[2], Abdul Wajid[3], Umair Khan[4], Aneeza Waris[5], Muhammad Bilal Aslam[6],Muhammad Wajid Munir[7]

*[*1,3]MS Allied Health Sciences, Faculty of Allied Health Sciences, the Superior University, Lahore*
[2]Faculty of Allied Health Sciences, the Superior University Lahore,
[4]Medical Officer, DHQ Shiekhupura
[5]MS Allied Health Sciences, the Superior University,Lahore
[6]MS Allied Health Sciences, Faculty of Allied Health Sciences
[7]Pervaiz Elahi institute of Cardiology, Wazirabad

[*1]mahnuryousaf@gmail.com, [2]adnan.hafeez@superior.edu.pk, [3]Abdulwajidd1@gmail.com, [4]khanumair9219@gmail.com, [5]aneezawaris98@gmail.com, [6]Malikbilalaslam04@gmail.com. [7]wajidmunir97@gmail.com

Corresponding Author: *

DOI: https://doi.org/10.5281/zenodo.14744828

ABSTRACT

Ventilator associated pneumonia (VAP) is a most common intensive care unit (ICU) infection that effects those patients who are on mechanical ventilation or ventilator. It is a significant cause of mortality and morbidity in ICU patients. Incidence of VAP varies from patient to patient and health care setting ranging from 5% to 40%. This study aims to identify the most common microorganism that is responsible for VAP, to evaluate which part of the ventilator is most susceptible for the transmission of microorganism and to ruled out which antibiotic prophylaxis has good outcomes against the prevention of VAP. This cross-sectional study will be conducted in Mayo Hospital Lahore.138 patient is selected to diagnose the VAP with the help of an X-ray, pan sculture including tracheal tube secretions culture, blood culture, urine culture and chest ultrasound. This study result provides evidence-based decisions against antimicrobial stewardship and help to control the spread of resistance microbes. The is entered and analyzed using SPSS 25. Chi square is used for the statistical analysis. P-value of 0.05 or less will be considered as significant. 92 out of 138 trials (66.7%) were successful for Colistin Sensitivity. 99 out of 138 trials (71.7%) were successful for Pseudomonas aeruginosa. looking at the numbers, it turns out that about 64.5% of the patient, that is 89 individuals, they were satisfied with their treatment results. The Asymptotic Standard Error here is 0.051. The most prominent micro-organism in ICUs of mayo hospital is Pseudomonas aeruginosa, which is predominantly sensitive against colistin, and treatment satisfaction

with colistin is 100% according to results. Further researches are needed to explore parts of ventilator for biofilm formation of microorganisms, and sterilization protocols.

INTRODUCTION

Ventilator-associated pneumonia, or VAP for short, is a big deal when it comes to the health problems faced by critically ill patients who are on ventilators. There's been a ton of research out there, yet the best ways to figure out if someone has VAP and how to treat it are still kind of up in the air. It's interesting, even with all the preventive measures in place, VAP remains a pretty common issue for these vulnerable patients, leading to high rates of illness and, unfortunately, death. It is just one of those things despite our efforts to keep it at away, VAP continues to show up and cause serious complications, preventing it is super important. But when VAP does strike, managing it effectively becomes essential. We really want to reduce the further complications, mortality, and the soaring medical costs that come with it. At the end of the day, diagnosing and treating VAP are really the main pieces of the puzzle we need to focus on. VAP is difficult to diagnose. (1) **.** Clinical and radiological criteria for VAP occurrence at the bedside are neither sensitive or specific. Lung tissue culture and histopathologic analysis continue to be the gold standard for diagnosing VAP. However, this method has not been used for the usual medical diagnosis of VAP because it is intrusive and has hazards. To condense and convert this knowledge on VAP prevention, diagnosis, and therapy into actionable suggestions, thorough professional guidelines are required, considering the sheer number and complexity of published trials pertaining to VAP. Consequently, an updated evidence-based medical guideline for the avoidance, detection, and treatment of VAP was developed by the Canadian Critical Care Trials Group. Our recommendations for the diagnosis and management of VAP are presented here. This edition also includes information on VAP preventive guidelines.

(2). Numerous factors, such as the quantity and toxicity of microorganisms in the lower respiratory tract, body defense systems, and the acquisition of germs living in the hospital environment, affect the start and severity of VAP. It is very recommended that the infection be confirmed by microbiology. The best sampling technique is still up for debate. In the near future, new microbiological technologies will probably change how we currently diagnose and treat VAP. Reducing exposure to mechanical ventilation and promoting early liberation are the cornerstones of VAP prevention. Although large randomized trials are required to validate this, bundles that integrate different preventative methods may enhance outcomes (3). In the great majority of cases, treatment should be restricted to seven days. Clinicians should think about halting medicines if cultures are negative, narrow the medications as soon as antibiotic susceptibility results are available, and revisit patients every day to confirm continued suspicion of disease (4). While mortality is mostly determined by the severity of the patient's illness and underlying diseases, VAP is linked to longer periods of mechanical breathing and prolonged ICU stays.

To better understand the varying contributions of the underlying disease, the kind and number of organ failures, as well as the pathogen identification and resistance profile, to the risk of death linked to VAP, future research should concentrate on more homogeneous patient groups. Clinical suspicion, new or progressive and persistent radiographic infiltrates, and positive microbiological cultures from lower respiratory tract specimens are the three criteria that are commonly used to diagnose VAP (5) **.** VAP can make it difficult for patients to wean themselves off of the ventilator and lengthen their hospital stays, which puts a significant financial strain on patients and increases the need for medical services. In the clinic, a variety of methods, including medications such probiotics, β-lactam antibiotics, and chlorhexidine, have been employed to prevent VAP. With the introduction of prophylactic strategies in recent decades, VAP's incidence and fatality rate have reduced; yet, it continues to rank among the leading causes of nosocomial

infections and deaths in the critical care unit. The absence of the highest standard for diagnosis, the lack of efficient prevention measures, and the increase in antibiotic resistance were the current issues in the care of VAP (6).

The international risk factors for VAP occurrence that have been disclosed in recent years are reviewed in this paper. These include patient characteristics, longer hospital stays and increased mechanical ventilation time, injuries, multiple disorders, previous antibiotic therapy, invasive procedures, gene polymorphisms, and problems of awareness. The equivalent preventive measures are also mentioned. Each component influences the others in addition to being a separate risk factor for VAP. Reducing the morbidity and death rates of VAP patients, preventing and controlling VAP, and forecasting its onset all benefit from a better understanding of risk factors (7). The normal airway's mucosal defensive function is altered by the artificial airway created by mechanical ventilation. It impairs swallowing abilities and cilia's ability to scavenge mucus. Infection is caused by bacteria that either enter the lower respiratory tract directly or enter through the opening between the airway and the tracheal tube wall. Furthermore, prolonged ventilation raises the danger of infection, which is brought on by humidification devices and ventilator circuits that expose people to the virus. Most intensive care units are confined spaces with irregular air circulation (8). Numerous bacteria that cause air contamination can be found in the exhaled gases and secretions of intensive care unit patients. An extended hospital stay also increases the risk of contracting hospital-acquired infections. Semiquantitative isolates of endotracheal aspirates or sputum combined with preliminary microscopic analysis determine the etiologic cause of pneumonia (9).

The majority of microbiology labs describe outcomes in a semiquantitative manner, characterizing growth as either light, moderate, or robust. Tracheal aspirate cultures regularly produce more bacteria than invasive quantitative cultures. A tracheal aspirate culture rarely lacks the pathogen or pathogens present in invasive quantitative infections. When combined with culture data, Gram staining of polymorphonuclear leukocytes and macrophages and close inspection of the architecture of any bacteria detected may increase the veracity of the diagnosis (10). There are quite a few factors that can lead to the development of ventilator-associated pneumonia (VAP). First off, endotracheal intubation stands out as the biggest risk.it interferes with the airway’s natural defenses and makes it harder for the body to clear out mucus, and then there is the length of time patient is on mechanical ventilation. This is important too. After about 10 days of being intubated, the risk of developing VAP really starts to shoot up. Now, if a patient has taken antibiotics before, that can throw the normal bacteria in their body out of whack. This disruption can pave the way for tougher, resistant bacteria to take hold. Plus, if someone has other health issues like acute respiratory distress syndrome (ARDS), septic shock, or chronic lung problems (11). They are even more at risk a variety of realistic and scientifically supported tactics that medical practitioners can use in their work to prevent VAP and lower its prevalence. The standard and execution of safety patient care can also be further supported and enhanced by the implementation of modern methods, equipment advancements, and multidisciplinary care packages. Ventilator-associated pneumonia, it's really tied to a bunch of different pathogens. The usual suspects like Pseudomonas aeruginosa, MRSA—which is short for methicillin-resistant Staphylococcus aureus—Enterobacter species, Klebsiella pneumoniae, and Escherichia coli are often the ones we find most often. What’s super concerning is the rise of antibiotic-resistant bacteria.

This whole situation makes treatment a lot trickier, it can lead to worse outcomes for patients. One of the main ways VAP develops is through something called micro aspiration, where secretions from the throat that have harmful bacteria get into the lungs (12). This position helps to stop any gastric contents from getting into the lungs, which is a real concern. Studies and clinical guidelines back this approach up, showing that it can help keep VAP rates down. Most important thing is subglottic secretion drainage for prevention of VAP.

Basically, it means using a special endotracheal tube with a cuff that lets us keep draining the secretions that build up above it (13). This method has been linked to a noticeable drop in VAP cases. regularly check the cuff pressure, too. Making sure that cuff is inflated just right is crucial to avoid any aspiration of secretions. So, in short, it's a collaboration of good oral care, some clever tube management, and tube management (14). When it comes to catching VAP early, timely intervention is key. A combination of clinical signs, imaging results, and microbiological data can really help in diagnosing it. There are clinical scoring systems, like the Clinical Pulmonary Infection Score (CPIS), that do a solid job of assisting in this process (15).

To really pin down the root causes, cultures from the respiratory secretions have to be taken to figure out what organisms are there and how they respond to antibiotics. It's crucial for picking the right empirical therapy. Antibiotic chosen after culture studies results in more treatment satisfaction (16). The goal here is to develop and implement some solid, evidence-based interventions that can help prevent VAP like those ventilator care bundles and various infection control measures. These strategies are specifically designed to reduce the rates of VAP in intensive care units, which is super important (17). It is important to think about how we can use what this study found to improve clinical management. One key takeaway is the need for quick diagnosis. Catching issues early is crucial, and then there is the sensible use of antibiotics, we need to be careful with those. Practicing infection control measures in ICU can help in reduction of VAP contamination. Endotracheal tube care, and cleaning play important role. we should focus on developing solid treatment guidelines for VAP among patients in the ICU. The study's results guide us here that by working towards these recommendations, we're not just checking boxes, we're aiming to deepen our understanding of VAP. Ultimately, this could lead to better care for our patients and improved management strategies in critical care settings (18).

It is one of among evidence-based practices. Starting empirical antibiotic therapy is super important. It really depends on a patient's specific risk factors and how local resistance patterns look. Studies have shown that when patients with VAP get the right treatment early on, they tend to do better. To help prevent antibiotic resistance from becoming a problem, it's wise to think about de-escalating the antibiotic treatment once we have the culture results. Basically, this means shifting from those broad-spectrum antibiotics to something more targeted based on the susceptibility profiles. It's all about finding the right balance When it comes to really sick patients, making sure they get enough food is super important. It is not just about keeping them full; it actually helps their immune systems get stronger and can speed up recovery. If it is possible, enteral feeding—basically feeding through a tube—is the way to go because it can help reduce the chances of infection and keeps the gut working well. on the breathing side of things, we can tweak ventilator settings to improve oxygen levels and lower the risk of further lung damage. Sometimes, using noninvasive techniques for breathing support can be really helpful too. There's still a lot we need to learn. As microbial resistance patterns change, we have got to dive deeper into research. This study is all about figuring out the most common germs associated with Ventilator-Associated Pneumonia（VAP）. By doing this, we hope to improve how we manage VAP and ultimately make our prevention and treatment strategies in critical care better. It's a crucial step forward. The goal here is to utilize sensitivity testing along with microbiological culture techniques. This will help us figure out which microbes are typically behind ventilator-associated pneumonia (VAP) They found that using ventilator care bundles really helped cut down the rates of ventilator-associated pneumonia in patients who were in the ICU. And then there is the work by Zilberberg et al. from 2014 (20). They really underscored how crucial it is to have proper antibiotic treatment, which not only improves clinical outcomes but also brings down the mortality rates linked to VAP. It is clear that these techniques can make a real difference (21). VAP is difficult to diagnose. Clinical and radiological

criteria for VAP presence at the bedside are neither sensitive or specific. Lung tissue culture and histopathologic analysis continue to be the gold standard for diagnosing VAP.

However, this method has not been used for the usual clinical identification of VAP because it is intrusive and has hazards. In clinical practice, specimens for microbiological cultures are obtained using both invasive (bronchoscopeic and nonsurgical (endotracheal aspirates) methods; nevertheless, there is disagreement on whether method is better. Uncertainty also surrounds the best antimicrobial agents and how long to treat VAP. Higher rates of morbidity and mortality are linked to delays in receiving the proper treatment. Recent trials have proven that treatment time can be safely decreased from typical 2-week courses, that antibiotic methods of management improve consequences, and that antibiotic withdrawal based on objective criteria minimizes antibiotic use without negatively influencing the clinical result. A meta-analysis that found higher fatality rates linked to incorrect first treatment with antibiotics for VAP emphasized the importance of effective antibiotic therapy. This emphasizes the necessity of strong practices and guidelines to guarantee that patients receive the right kind of first antimicrobial treatment. Furthermore, there are regional variations in the prevalence and vulnerability profiles of pathogens linked to VAP. Enhancing the precision and efficacy of empirical treatment plans requires an awareness of these geographical variations, which in turn helps to achieve the crucial objective of reducing the improper use of broad-spectrum antibiotics. (24).

The main aim of this study is really about figuring out, assessing, and then actually implementing effective ways to prevent the most common bacteria that lead to ventilator-associated pneumonia, or VAP, in patients who are in intensive care units, or ICUs. It is a big deal because these infections can be quite serious. By focusing on specific interventions, we hope to make a positive difference in patients' lives. We are also looking to evaluate how these bacteria respond to antibiotics – that's the patterns of antibiotic susceptibility; there's the whole other layer where we want to dig deeper into understanding the microbial ecosystem that's connected to VAP. It is fascinating and important for better patient care. The goal here is to utilize sensitivity testing along with microbiological culture techniques. This will help us figure out which microbes are typically behind ventilator-associated pneumonia (VAP) in patients in the ICU. It's also important to look at the clinical implications that come with certain infections, especially those caused by Pseudomonas aeruginosa. Understanding these relationships can be crucial for improving patient outcomes. We are looking into how sensitive certain germs are to antibiotics. Specifically, we want to see how well colistin works against Pseudomonas aeruginosa.

It is essential to know how often these bugs are resistant to multiple drugs because that can really mess with how we treat infections. there's this other thing: we need to check how satisfied ICU patients with Ventilator-Associated Pneumonia (VAP) are with their treatment. We used some solid satisfaction scales for that and then compare those results to what we find microbiologically. we should also think about what factors might be affecting how these patients feel about their treatment. What influences their satisfaction, it's all interconnected, and understanding all these elements will help in figuring out better treatment strategies (25).

METHODOLOGY

This cross-sectional descriptive study was conducted to identify, evaluate, and mitigate the predominant microorganisms responsible for ventilator-associated pneumonia (VAP) among ICU patients. The study was carried out in the intensive care unit (ICU) of Mayo Hospital Lahore, a tertiary care center equipped with advanced critical care facilities. The ICU provides comprehensive care for patients with life-threatening conditions requiring mechanical ventilation, offering modern monitoring systems and a dedicated team of intensivists, anesthesiologists, and trained nursing staff to ensure round-the-clock care. The sample size for the study was determined using Cochran's formula, which provided a statistically reliable sample size of 138

patients. This calculation assumed a prevalence rate of 15% and a margin of error of 5% at a 95% confidence interval.

A random sampling technique was employed to ensure unbiased selection of participants. Patients admitted to the ICU and meeting the inclusion criteria were recruited for the study. Inclusion criteria specified that participants must be adults aged 18 years or older, requiring mechanical ventilation for more than 48 hours, and have clinical and microbiological evidence of VAP. Patients with non-ventilator hospital-acquired pneumonia or those in wards or operating room settings were excluded from the study. Data collection involved a combination of clinical assessments, microbiological sampling, and review of patient records. Clinical assessments included monitoring symptoms such as fever, productive sputum, and changes in lung sounds. Microbiological samples, including endotracheal aspirates and bronchoalveolar lavage, were collected to identify causative pathogens and their antibiotic sensitivity profiles. Patient records were systematically reviewed to document demographic information, comorbidities, duration of mechanical ventilation, and antibiotic usage.

Strict aseptic techniques were employed during all procedures to minimize the risk of contamination, and data were documented in a standardized format to ensure accuracy and consistency. Ethical approval for the study was obtained from the Institutional Review Board (IRB) of Mayo Hospital Lahore. Informed consent was acquired from patients or their legal representatives before their inclusion in the study. Confidentiality was strictly maintained by anonymizing all collected data to protect patient privacy. Data analysis was performed using SPSS version 25. Descriptive statistics such as means, standard deviations, and frequencies were used to summarize demographic and clinical data. Statistical tests, including chi-square and paired-proportion analyses, were employed to assess the associations between microbial prevalence, antibiotic sensitivity, and treatment satisfaction. A p-value of less than 0.05 was considered statistically significant. The comprehensive methodology adopted in this study ensured robust data collection and analysis, contributing to the reliability and validity of the findings.

RESULTS

Table 1.1: Socio demographic Variables with their percentage, mean and S.D

Variables	Frequency		Percentage	Mean	Standard deviation
Age	**15-30**	**25**	**18.1%**	34.7	±13.22
	31-50	**85**	**61.5%**		
	51-70	**28**	**20.2%**		
Gender	**Male**	**102**	**63.7%**	0.36	±0.482
	Female	**58**	**36.3%**		
pseudomonas aeruginosa (1=present, 0=Not present)	**0**	**39**	**27.7%**	0.72	±0.452
	1	**99**	**70.2%**		
Sensitive to colistin (1=Yes, 0=No)	**Sensitive (1)**	**46**	**65.2%**	0.33	±0.471
	Non-sensitive (0)	**92**	**32.6%**		
Treatment Satisfaction	**1=satisfactory**	**89**	**63.1%**	0.64	±0.480
	0=Not satisfactory	**49**	**34.8%**		



Figure 1.1 Graphical view of gender and its frequency and percentage

In our study, four demographic variables gender, age, pseudomonas aeruginosa, sensitivity to colistin, and treatment satisfaction are Included. Age is categorized into three groups 15-30, 31-50, and 51-70 years. Table 1.1 depicts 25 patients are from to the age group 15-30 with percentage 18.8%. 85 patients are from to the age group 31-50 years old and percentage is 61.5%. 28 patients belong to the age group of 51-70 years with percentage 20.02%. Age has 34.7 mean with standard deviation ±13.226. These results depicts that mostly patients in this research are the age group 31-50 years old. 58 patients are female and 108 patients are female. Gender has a standard deviation ± 0.482, and 0.36 mean. These numbers show that female is less in numbers than male in our research. 138 patients have Ventilator Associated Pneumonia and their percentage is 100%. 99 patents out of 138 have Pseudomonas Aeruginosa as predominant microorganism in their culture studies with percentage of 70.2%. Mean for Pseudomonas Aeruginosa is 0.33 with standard deviation ±0.47. These Results shows that most common microorganism is pseudomonas aeruginosa on culture of tracheal aspirate. Overall, 138 patients are present in this research, and all of patients were having VAP. Results from table show that patients are more sensitive to colistin against pseudomonas aeruginosa. 92 patients out of 138 are sensitive to colistin with mean of 0.33 and standard deviation is ±0.471. While 46 patients were not sensitive to colistin with percentage of 32,6%. Sensitive to colistin patients are termed as 1, while non-sensitive patients are nominated as 0. Sensitivity to colistin shows 65.2%. In our research treatment satisfaction is also calculated in patients those are treated with colistin, or culture sensitive antibiotic against VAP. Satisfactory treatment is termed as 1, while not satisfactory is termed as 0. Results from table 1.1 shows 89 patients had satisfactory treatment against VAP with colistin, and overall percentage is 63.1%. While 49 patients out of 138 were not sensitive to colistin or had non satisfactory treatment. Mean for treatment satisfaction is 0.64, and standard deviation is ±0.480. See Table 1.1.

Table 1.2: Association between Pseudomonas Aeruginosa, Sensitivity to Colistin, and Treatment Satisfaction in Paired-Samples Proportions Statistics

Pair 1	Successes	Trials	Proportions	Asymptotic Standard Error
pseudomonas aeruginosa (1=present, 0=Not present) = 1	99	138	0.717	0.45
Sensitive to colistin (1=Yes, 0=No) = 1	92	138	0.667	0.49

Pair 2	Successes	Trials	Proportions	Asymptotic Standard Error
1=satisfactory, 0=Not satisfactory = 1	89	138	0.645	0.051
VAP (1=present, 0=Not present) = 1	138	138	1.000	0.000

In this work, we aimed at determining the antibiotic susceptibility and rate of the most common bacteria associated with VAP in ICU patients. Proportion test is taken into two pairs, pair 1 is for P. aeruginosa, and senstivity to colistin. Pair 2 is for treatment satisfaction, and VAP. From Collected data on the presence of P. aeruginosa, its behaviour to colistin and overall satisfaction with the treatment outcomes was assessed with the paired-samples proporticons. Table 1.2 shows chi square test proportion test, that shows trials, proportion, amd success of trials with asyptotic error or p value. Table 1.1 first row shows that 138 trials are taken for iidentification of most prominant microrganism, which turned out that 99 patients are positiive for Pseudomonas aeruginosa. Proportion is 0.717, and p value is 0.45, which shows that among the 138 trials conducted, 71.7%（actually 99 were successfully completed against psuedomonas auregenosa. 0.045 refers to the asymptotic error. This implies that Pseudomonas aeruginosa is very prevalent among the ICU individuals who develop VAP. Pair 2 includes identification of microorganism, and treatment satisfaction with colistin. VAP presense is termed as 1, and absence is named as 0 in SPSS analysi. Table 1.2 shows that 130 patients had ventilator assopciated pneumonia, 92 were sensitive to colistin, and 89 had treated succesfully with colistin with proportion of 0.645, and p value is 0.05. For colistin semsotivity 66.7% of the 92 out of 138 trials were successful and the asymptotic standard error is 0.049. A significant percentage of the Pseudomonas aeruginosa samples were observed to be colistin-sensitive and therefore have a potential in the treatment of infections by this microorganism. The comparatively high degree of satisfaction with results from treatment indicates that most patients felt their interventions had positive effects: 89 Of the 138 trials (64.5%). Asymptotic Standard Error: 0.051. The severity of VAP in the intensive care unit is shown by the fact that it was verified in all of the study participants. The severity of VAP in an intensive care unit is shown by the fact that it was confirmed in all of the study participants. The findings of this study show that Pseudomonas aeruginosa is highly responsive to colistin and is a prevalent infection in VAP within ICU patients. Given the significant incidence of VAP in the community being studied, effective treatment strategies and ongoing surveillance are necessary. The intermediate satisfaction percentages suggest that, despite the treatment's generally good results, the results for patients could be enhanced. The significant difference in levels of satisfaction when compared with when VAP was present highlights the need for better management strategies to improve the experiences and outcomes of patients in this critical care context.



Figure 1.2 Graphical representation of Pseudomonas aeruginosa, and treatment satisfaction



Figure 1.3 Graphical representation of Sensitivity to colistin, and treatment satisfaction

Table 1.3 Cross tabulation of Treatment satisfaction (1=satisfactory, 0=Not satisfactory) & Sensitive to colistin (1=Yes, 0=No)

Count		**Count**		**Count**
		Sensitive to colistin (NO:0)	Yes (1)	**Total**
Not Satisfactory	**0**	**19**	**30**	**49**
Satisfactory	**1**	**27**	**62**	**89**
Total		**46**	**92**	**138**

Table 1.3 shows cross tabulation between variables. The statistical analysis's p-value of 0.05 indicates that the estimated fractions of Pseudomonas aeruginosa existence, colistin sensitivity, and treatment satisfaction are statistically significant. The p-value shown by the analysis disapproves this null hypothesis suggesting that the formation of the research's variables has a 5% chance of generating the observed result. This assessment compared the mean of satisfaction with treatment outcomes to the presence of VAP and found a variance in proportions of -0.355, CI 95% CI ranged from -0.431 to -0.269. This negative difference makes it possible to claim that patients do not have a high satisfaction rate where VAP is in operation and this is way

below the satisfaction rates when VAP is not in existence. The observed modifications in proportions are statistically significant at 0.05 for the entire analysis. This p-value is thus an assertion that there is a 5% chance that results given by the null hypothesis that which states that the variable under study have no relationship at all will be observed.

DISCUSSION

VAP is a significant complication to patients admitted to the ICU and, indeed, it worsens the morbidity and mortality ratio of critically ill individuals. Pseudomonas aeruginosa is one of the most frequently isolated bacteria, and these bacteria must be known and considered in order to enhance patient results. This discussion chapter gives an overview of our study and highlighted on successful prevention, significant figures and its implication on treatment satisfaction. The incidence of VAP varies significantly and was estimated to be between 7% and 70% based on the study (see table 1.1). we have concluded that P. aeruginosa is most prominent microorganism among all microbes causing VAP. P. Aeruginosa is appeared to have mean of 0.72 with standard deviation of ±452 (see table 1.1). Among all the pathogens in our study, the leading was Pseudomonas aeruginosa, which has been reported in other investigations with reference to increased resistance rates and poor clinical prognosis related to this bacterium. By achieving statistical credibility to our enquiry and the materials about identification, the evaluation, and prevention of the most common bacteria causing VAP in patients in the ICU, we rejected the aforementioned null hypothesis. In the treatment satisfaction study, the p-value obtained, 0.05, shows that the chance of the observed difference in satisfaction with the results of the treatment being due to random variation is slim (see table 1.3). This result provides evidence of the efficacy of our treatments for VAP as well as support for more specific approaches for better patient outcomes. That p-value points toward the conclusion that how we recognize and address the chief psychophysical pathogens (or germs), particularly Pseudomonas aeruginosa, factors into patient ICU satisfaction. These findings therefore suggest the continued importance of maintenance of ICUs and prevention measures in the setting P. aeruginosa are significantly sensitive to colistin with standard deviation of 0.473, and p value is 0.04 (see table 1.2).

Our investigation made use of a strong diagnostic framework that evaluated clinical symptoms and microbiological cultures. Reliance on precise microbiological testing is essential since it has a direct impact on the empirical antibiotic medication selection. A diversified strategy is required to treat VAP, especially in light of antibiotic resistance. The quantities of Pseudomonas aeruginosa existence and sensitivity to colistin differed significantly, according to our data. According to the paired-samples proportions analysis, the difference was 0.051, with a 95% CI between -0.059 and 0.159 (see table 1.3). Although this points to a positive trend in sensitivity, the difference could not be statistically significant because the confidence interval contains zero. This emphasizes how important it is to continuously monitor antibiotic susceptibility patterns in order to guarantee successful therapy. Additionally, a significant proportional difference of -0.355 was found when comparing treatment satisfaction to the existence of VAP, with a 95% confidence interval spanning from -0.431 to -0.269 (see table 1.3). That is why an unfavorable difference presented above is indicative of the necessity of improving the management techniques, as patient satisfaction with treatment outcomes in the case of VAP is significantly lower. A small confidence interval indicates a high level of precision of the estimate, so the interest in the patient's concerns during VAP treatment seems crucial.

Ventilator-Associated Pneumonia is prevented with measures such as selective oropharyngeal and digestive tract decontamination, which are especially effective in previously low antibiotic resistance units like the ICUs. The key message is that the prudent use of antibiotics in relation to culture results and the need to reduce resistance in treating patients. This highlights the need to use right antibiotic at the correct time from

the susceptibility testing results. In order to make sure that antibiotics are prescribed and utilized as and when required for the particular infections which have been defined by culture results, an effective antibiotic stewardship should be embarked. Significance of p-value also highlights that how best we find/recognize most common germs, with P. aeruginosa being the worst germ, impacts patient satisfaction levels, a key focus in ICU. According to culture findings, even though this pathogen routinely causes infections and is exceptionally sensitive to colistin, it stresses the need for correct and timely antibiotic administration. Moreover, the consistent relationship between the successful microbial stewardship and patient satisfaction stresses the need for proper infection control measures, and prudent use of antibiotics in the ICU.

Observing the findings, it can now be concluded that when doctors carefully diagnose and treat VAP through using sound knowledge and practices, patients get satisfied. This is important for the standard of care, not to mention, for the overall recovery. The failure to accept null hypothesis not only supports our research approach but also establishes that educational and training for the medical staff should continuously be offered in VAP management. Taken together, these findings support the model of care for VAP prevention which implies patient-centered approach, timely approach, and microbiological monitoring. This together with the fact that we may be able to enhance treatment satisfaction and later medical conditions of ICU patients susceptible to VAP by adjusting our strategy and focusing on the main pathogens that affect our clients. This study points out the fact that there is need for continued observation in infection control and also point out the need for continuous assessment.

To reduce the probability of antibiotic resistance in case management, you should avoid liberal usage of antibiotics such as amoxicillin in forms not justified by the necessity of definite signs of active microbial infection. Obtain cultures first before starting the antibiotic medication so that the correct choice of antibiotic is based on fact. Due to this, the specific type of antibiotics can be chosen because the infections and their resistance indexes have been virtually determined. Controlling water and preventing the breeding of vectors, especially in areas of humidity is also very important measures in reducing a chance of infection. Our study underscores value of recognizing and assessing the principal pathogens that cause VAP, and eradicating methods of avoiding VAP in patients in ICUs. The results also indicated that there is a clear link between successful microbiological treatment and patients' satisfaction which points to the ongoing nature of the efforts towards preventing and controlling infections as well as antibiotics. Thus, this study aimed to improve the clinical efficacies and therapeutic satisfaction for ICU patients susceptible to VAP by fine-tuning the approached methods and concentrating on the main pathogens infecting our patients. From the findings of this study, the authors advocate for early intervention in VAP care; patient involvement; epidemiological monitoring as well as looking at the strategies of patient care ahead of this ailment.

Recent studies reveal that the microbial pattern of VAP has changed and the common organism now is Pseudomonas aeruginosa. These results are supporting the previous scientific works, which proved that this bacterium is often related to the antibiotic resistance and thereby causes a problem with the treatment. The SENTRY antimicrobial monitoring program identified Pseudomonas aeruginosa as one of the most common causes of nosocomial pneumonia, underscoring the significance of focused antibiotic stewardship. The substantial association between Pseudomonas aeruginosa prevalence and treatment satisfaction demonstrates the need for stringent infection control measures. Following hand hygiene instructions, properly sterilizing medical equipment, and routinely cleaning the environment are essential to preventing the spread of this infection. Healthcare workers must be continuously educated and trained in the management of VAP. Our findings are consistent with a multidisciplinary approach that promotes collaboration amongst healthcare providers to raise the overall standard of medical treatment for patients in intensive care units. As noted by Klompas, the development of simplified definitions for VAP could improve the accuracy of diagnosis and

enable immediate action (15). Our study combined clinical lung infection scores with microbiological cultures following guidelines from the ATS/IDSA. However, considering the fact that multidrug-resistant pathogens are present quite often, VAP treatment is a very complex process. Use of accurate diagnostic metrics is important since incorrect diagnosis leads to the prescription of antibiotics, which only worsen resistance.

These data show that the level of treatment satisfaction significantly differs between VAP patients and this requires effective interventions. The studies about the application of ventilator care packages, which are the measures like positioning of the head of the bed and oral care as the means to decrease VAP rates; the difficulties in the implementation of these bundles indicate the necessity of the education and training of the heath care workers; the importance of the environmental cleaning and disinfection in the prevention of the VAP; and the necessity of the constant study of the infection control measures and environmental surveys. The management of VAP in ICU involves diagnosis, putting in place a proper treatment system and a profound preventive system. Adding to what we have found, our data aligns with previous research in stress in the developing pathogen profiles and immune patterns for VAP. It is possible to reduce the burden of VAP on finances and care of the critically ill patients in the ICU through early promotion of antibiotic stewardship, improvement of diagnostic accuracy, and early complete implementation of infection control measures. The future research should be directed on the further improvement of the existing approaches and the development of the new ones for managing the infection. Treatment satisfaction with colistin against p. aeruginosa is 66.6%, and p value is 005. 92 patients out of 138 were treated successfully with colistin (see table 1.2).

CONCLUSION

In this study, we were able to discover and assess the major bacterial pathogens of VAP in ICU patients with a focus on PA. In our study, we observed a high level of detection of this pathogen with 99 of 138 (71.7%) trials reporting a positive test for the relevant patients. Additionally, we examined the efficacy of colistin on Pseudomonas aeruginosa out of 138 trials, 92 (66.7%) was sensitive to colistin, which still make it an appropriate treatment for those who are infected with this bacterium. This just goes to show how desperately people need proper screening and treatment measures to combat the disease. Because Pseudomonas aeruginosa is ubiquitous, and colistin is highly effective against this organism, culture-directed appropriate and timely antibiotic use is critical for reducing morbidity and mortality. The study also clearly reveals the need for proper antibiotic stewardship programs along with frequent monitoring of microbial resistance in an effort to gain maximum potential and reduce the emergence factors of resistance. All the patients in the analysis had VAP diagnosis and the present research underscored the role of VAP in the ICU. In view of these findings, this study establishes the need for specific preventative measures in order to minimize the incidence and consequences of this often-fatal virus and provides additional information regarding the epidemiology of VAP in patients in intensive care units. It is imperative of future studies research the dynamics of microbial resistance and the efficacy of different treatments in order to improve patient outcomes in the intensive care unit

LIMITATIONS

Longitudinal studies are suggested to compare changes within periods and to understand regularities in the organisms that cause VAP. Seasonal variability of the changes in frequency and patterns of resistance in microorganisms could not have been covered adequately by the time period assessed in the study. The

sample comprised of 138 patients which reduced the generality of the results that were obtained. A larger sample size would produce even more reliable results and much more meaningful data.

RECOMMENDATIONS

Encourage heavily a team approach to VAP management that involves the intensivist, the nurse, the pharmacist, and the infectious disease specialist. This will provide good coverage thus enhancing improved patient care. Encourage further investigations into development of VAP, including such issue as efficacy of various therapies, impact of preventive measures, and long-term prognosis of the VAP patients. This will help in coming up with the right management for this complicated disease

REFERENCES

Teoli J, Amour S, Dananché C, Dauwalder O, Gerbier-Colomban S, Mauranne CC, Zorio V, Monard C, Arnal S, Friggeri A, Lepape A. Trends in the proportion of resistant bacteria involved in ventilator-associated pneumonia as the first hospital-acquired infection in intensive care units between 2003 and 2016 in Lyon, France. American Journal of Infection Control. 20211;49(11):14-46.

Kao HH, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, Chen CM, Shen YC, Zheng ZR, Lin YT, Hsu HS. Ventilator dependence in critically ill patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter observational study. Journal of critical Care medicine. 2021;11(1) 2-11

Martinez-Reviejo R, Tejada S, Jansson M, Ruiz-Spinelli A, Ramirez-Estrada S, Ege D, Vieceli T, Maertens B, Blot S, Rello J. Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis. Journal of Intensive Medicine. 2023 25;3(04):352-64.

Sosa-Hernández O, Matías-Téllez B, Estrada-Hernández A, Cureño-Díaz MA, Bello-López JM. Incidence and costs of ventilator-associated pneumonia in the adult intensive care unit of a tertiary referral hospital in Mexico. American journal of infection control. 2019 1;47(9):21-5.

Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Critical care medicine. 2008 1;36(1):108-17.

Tehan PE, Browne K, Matterson G, Cheng AC, Dawson S, Graves N, Johnson D, Kiernan M, Madhuvu A, Marshall C, McDonagh J. Oral care practices and hospital-acquired pneumonia prevention: A national survey of Australian nurses. Infection, disease & health. Infection Disease and Health. 2024 8;29(2): 2-6.

Young PJ, Delaney A, Hills T. Ventilator-associated pneumonia: A problematic outcome for clinical trials. Critical Care and Resuscitation. 2023 ;25(4):159-161.

Young PJ, Delaney A, Hills T. Ventilator-associated pneumonia: A problematic outcome for clinical trials. Critical Care and Resuscitation. 2023 ;25(4):159-161.

Moro H, Aoki N, Matsumoto H, Tone K, Shuto H, Komiya K, Bacterial profiles detected in ventilator-associated pneumonia in Japan: A systematic review. Respiratory Investigation. 2024;62(3):365-8.

Livesey A, Quarton S, Pittaway H, Adiga A, Grudzinska F, Dosanjh D, Parekh D. Practices to prevent non-ventilator hospital acquired pneumonia: a narrative review. Journal of Hospital Infection. 2024;3(23): 1-12.

Sano M, Shindo Y, Takahashi K, Okumura J, Sakakibara T, Murakami Y, Iguchi M, Yagi T, Matsui S, Hasegawa Y. Risk factors for antibiotic resistance in hospital-acquired and ventilator-associated pneumonia. Journal of Infection and Chemotherapy. 2022 1;28(6):745-52.

McAuley SM, Price RJ, Phillips G, Marwick CA, McMurdo ME, Witham MD. Interventions to prevent non-critical care hospital acquired pneumonia–a systematic review. European Geriatric Medicine.2015 1;6(4):336-40.

Mohamed MS, Elkhadrawy SM, Saleh MMEA, El-Shandawelly MSI. Comparative study between percutaneous and open transpedicular fixation in thoracolumbar fractures. NeuroQuantology. 2021;19(1):165-169.

Fortaleza CM, Ferreira Filho SP, de Oliveira Silva M, Queiroz SM, de Souza Cavalcante R. Sustained reduction of healthcare-associated infections after the introduction of a bundle for prevention of ventilator-associated pneumonia in medical-surgical intensive care units. The Brazilian Journal of Infectious Diseases. 2020 1;24(5):373-9.

Russell CD, Koch O, Laurenson IF, O'Shea DT, Sutherland R, Mackintosh CL. Diagnosis and features of hospital-acquired pneumonia: a retrospective cohort study. Journal of Hospital Infection. 2016 1;92(3):3-9.

Parajuli NP, Acharya SP, Dahal S, Singh JP, Mishra SK, Kattel HP, Rijal BP, Pokhrel BM. Epidemiology of device-associated infections in an intensive care unit of a teaching hospital in Nepal: a prospective surveillance study from a developing country. American journal of infection control. 2017 1;45(9):1024-9

Li L, Wang Q, Wang J, Liu K, Wang P, Li X, Yang J, Lu J, Li D, Wang L, Wang Z. Development, validation and application of a ventilator-associated pneumonia prevention checklist in a single cardiac surgery centre. Intensive and Critical Care Nursing. 2018 1;49:58-6.

Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, de Donato G, Eckstein HH, De Rango P, Diehm N, Schmidli J, Teraa M. Chapter I: definitions, epidemiology, clinical presentation and prognosis. European Journal of Vascular and Endovascular Surgery. 2011 1;42:4-12.

Qiao L, Zuo W, Yang Y, Liu X, Wang Q, Yu J, Wu J, Xu T, Jiang J, Zhang B, Long Y. Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia. International Journal of Antimicrobial Agents. 2023 1;62(2):106-880.

Bian X, Liu X, Feng M, Bergen PJ, Li J, Chen Y, Zheng H, Song S, Zhang J. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents. 2021 1;57(2):106-271.

Hardalo C, Edberg SC. Pseudomonas aeruginosa: assessment of risk from drinking water. Critical reviews in microbiology. 1997 1;23(1):47-75.

Kloos WE, Schleifer KH. Simplified scheme for routine identification of human Staphylococcus species. Journal of clinical microbiology. 1975 ;1(1):82-8

Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical microbiology reviews. 1998 1;11(4):589-603.

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 2008 ;21(3):538-82.

Hoffmann H, Roggenkamp A. Population genetics of the nomenspecies Enterobacter cloacae. Applied and environmental microbiology. 2003 ;69(9):5306-18.

Pneumatikos IA, Dragoumanis CK, Bouros DE, Warner DS, Warner MA. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. The Journal of the American Society of Anesthesiologists. 2009 1;110(3):673-80.

Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive care medicine. 2012 ;38:263-71.6